TB-500 cost: what a prescription costs, and what research-grade vials lack
Published prices by program type, checked November 2, 2026. REMEVi does not currently price TB-500.
Almost no programs publish a price for compounded TB-500 on its own. On November 2, 2026 we found one telehealth starting price and no clinic price for TB-500 alone. REMEVi does not currently price or offer TB-500. Below: what is published, what the 2026 policy’s sourcing rules add, and why research-grade vials cost less.
TB-500 is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.
REMEVi does not currently offer TB-500.
What compounded TB-500 costs, by program type
| Program type | Published price | What the price covers |
|---|---|---|
| Telehealth peptide programs | From $143 per month (injectable vial), posted before the program’s launch | The page says the final price will include the provider visit, medication if prescribed, and shipping |
| Clinic hormone and wellness programs | No published price found for TB-500 alone (checked 2026-11-02) | The clinic page we checked lists TB-500 inside a combined product, which the 2026 policy does not cover, and no price for TB-500 by itself |
| Research-grade vials | Not listed here (checked 2026-11-02) | Sold labelled for research use, outside the 2026 policy; this page does not link to those sellers |
Prices are what each publisher posted on the date checked. They change and they are not REMEVi prices. Publishers are named in the sources list.
What the CoA and registered-source requirements add
Under HHS’s 2026 policy, a compounded TB-500 prescription carries steps a research vial skips:
- Bulk TB-500 from an FDA-registered facility with a valid certificate of analysis, from a manufacturer that is FDA-registered and CGMP-compliant.
- Compounding by a state-licensed 503A pharmacy for one named patient, with TB-500 as the single active ingredient.
- A labelled product (“This is a compounded drug product. Not for resale.”) and a 510(k)-cleared syringe as the one packaged device.
- A prescriber’s evaluation, and serious adverse events reported to FDA MedWatch.
Each step is documentation, testing or clinical time, which is part of why a prescription costs more than a vial.
Why research-grade TB-500 is cheaper, and what it lacks
Research-use vials skip the prescriber, the pharmacy and the paperwork. What you give up:
- No prescription and no evaluation of whether it is appropriate for you.
- No licensed pharmacy answerable for identity, strength or sterility.
- No certificate of analysis tied to an FDA-registered source.
- No patient label, and no adverse-event reporting path.
- No coverage under the 2026 policy, including for premixed TB-500 + BPC-157 vials. FDA sent warning letters to five online peptide vendors on August 24, 2026.
REMEVi does not currently price TB-500
REMEVi does not offer TB-500 and has no TB-500 price. What REMEVi does offer uses the same prescription-and-licensed-pharmacy model:
How much does TB-500 cost per month?
Hardly anyone publishes it. On November 2, 2026, we found one telehealth program listing a starting monthly price in the low hundreds of dollars, posted before launch, and no clinic price for TB-500 alone. Research-use vials are excluded because the 2026 policy does not cover them. REMEVi does not currently price TB-500.
Sources
- HealthRX — TB-500 product page (“From … /mo”, listed before launch) (read November 2, 2026)
- Perfect B Aesthetic Medicine (Doral, FL) — How much does BPC-157 cost? (checked for a TB-500 price; none listed for TB-500 alone) (read November 2, 2026)
- HHS — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, notice of availability, 91 FR 68526 (October 30, 2026) (read November 2, 2026)
- Foley & Lardner (Holtz, Beaver, Rosen), National Law Review, Oct 30 2026 — Peptides: HHS announces limited enforcement discretion for compounding six peptides (read November 2, 2026)
- Holland & Knight, Oct 16 2026 — Peptides at a crossroads: what wellness providers need to know (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·